Redbiotec develops prophylactic vaccines, with a strong focus on HCMV (human cytomegalovirus).
Expansion: pure HCMV VLPs
Redbiotec has successfully assembled constructs leading to reVLPs® based on capsid and surface proteins from human cytomegalovirus (HCMV) only. Analyses including mass spectrometry and electron microscopy confirmed the presence of up to 11 HCMV proteins and showed the expected virus-like particles, further expanding Redbiotec’s leading programme of CMV vaccines.
Tackling Herpesviruses: data library
After Redbiotec’s achievements with the CMV vaccine development and based on the assembly power of its rePAX® platform, the company embarked on the creation of a Herpesvirus data library over the next years.
Redbiotec is convinced that this library will lead to the generation and optimization of Herpes vaccine candidates, and will eventually reveal potential causes of virus latency and help elucidate virus-triggered cancer mechanisms.
Dr. Permar is a leading scientist studying neonatal viral pathogenesis including congenital Cytomegalovirus (CMV) infection. Dr. Permar and her team utilize nonhuman primate models and human cohort studies to understand and elicit immune responses that can prevent vertical virus transmission.
Redbiotec’s team has the goal to develop the first CMV vaccine on the market and we are glad that Dr. Permar will scientifically support Redbiotec in its efforts.